Clinical Trial Limits Must Be Acknowledged In ADR Debate - FDA's Lumpkin
Reform of the pharmaceutical adverse event monitoring system must be based on a larger debate over the societal expectations for clinical research, Center for Drug Evaluation & Research Deputy Director Murray Lumpkin, MD, told a Drug Information Association/ General Accounting Office panel Feb. 24 in Washington, D.C.
You may also be interested in...
Stricter prescribing regulations may be one way to reduce the number of preventable adverse drug events, FDA Center for Drug Evaluation & Research Director Janet Woodcock, MD, suggested Nov. 17.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011